Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-06-16 HERSHBERG ROBERT Director Grant or award +12,612 38,619
2023-06-16 HERSHBERG ROBERT Director Grant or award · Stock Option (Right to Buy) +25,224 25,224
2023-06-16 Burrell Terry-Ann Director Grant or award +12,612 171,847
2023-06-16 Burrell Terry-Ann Director Grant or award · Stock Option (Right to Buy) +25,224 25,224
2023-06-16 CHAVEZ R. MARTIN Director Grant or award +12,612 51,017
2023-06-16 CHAVEZ R. MARTIN Director Grant or award · Stock Option (Right to Buy) +25,224 25,224
2023-06-16 Virani Shafique Chief Business Officer Exercise or conversion 10b5-1 +30,000 $2.22 $67K 173,954
2023-06-16 Virani Shafique Chief Business Officer Sale 10b5-1 −30,000 $9.41 $282K 143,954
2023-06-16 Virani Shafique Chief Business Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −30,000 569,469
2023-06-15 Virani Shafique Chief Business Officer Exercise or conversion 10b5-1 +30,000 $2.22 $67K 173,954
2023-06-15 Virani Shafique Chief Business Officer Sale 10b5-1 −30,000 $9.67 $290K 143,954
2023-06-15 Virani Shafique Chief Business Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −30,000 599,469
2023-06-15 Gibson Christopher Chief Executive Officer Conversion +10,000 926,378
2023-06-15 Gibson Christopher Chief Executive Officer Gift −10,000 916,378
2023-06-15 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −10,000 6,541,496
2023-06-14 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +37,500 $2.22 $83K 842,913
2023-06-14 Secora Michael Chief Financial Officer Sale 10b5-1 −25,000 $10.07 $252K 817,913
2023-06-14 Secora Michael Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −37,500 745,313
2023-06-13 Borgeson Blake Director Sale −15,485 $9.98 $155K 7,525,262
2023-06-13 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +37,500 $2.22 $83K 830,413

Page 38 of 41 · 805 trades